Comparison · NCT01274559-sae
Extended-release Niacin/Laropiprant vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Extended-release Niacin/Laropiprant vs Placebo: serious adverse events. Trial comparisons, record NCT01274559-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01274559-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0402 | 0.0269 | 0.0596 | wilson | |
| Risk in group 2 | 0.028 | 0.0173 | 0.045 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0122 | -0.00931 | 0.0344 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.44 | 0.768 | 2.69 | log | |
| Odds ratio, group 1 over group 2 | 1.46 | 0.761 | 2.79 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Extended-release Niacin/Laropiprant than on Placebo | 81.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Extended-release Niacin/Laropiprant | ERN/LRPT 1 g (1 tablet for 4 wks) followed by ERN/LRPT 2 g (2 tablets for 8 wks); Each 1-g tablet contains 1 g of ER niacin and 20 mg of laropiprant. | 23 | 572 | EG000 |
| Group 2 | Placebo | Matching 1 g Placebo (1 tablet for 4 wks) followed by 2 g placebo (2 tablets for 8 weeks) | 16 | 572 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- up to 12 weeks
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)
- NCT number
- NCT01274559
- Phases
- PHASE3
- Conditions
- Primary Hypercholesterolemia, Mixed Dyslipidemia
- Interventions
- Extended-release niacin/laropiprant (ERN/LRPT), Placebo
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2014-03-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01274559?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01274559-sae